title: Segmental gut transit in diabetes mellitus: effect of cisapride.
abstract: Gut transit using radiopaque markers was assessed in 5 healthy subjects and 24 diabetic patients. In the diabetics, various parameters including duration of the disease and diabetic complications, such as neuropathy, retinopathy and nephropathy, were determined, and the relationships between gut transit times and these complications were evaluated. The effect of cisapride on gut transit was studied in 10 diabetic patients. Large intestinal, descending colon, distal colon, and whole gut transit times were delayed in diabetics with autonomic neuropathy compared to controls and to diabetics without autonomic neuropathy (P less than 0.01). There was no difference in proximal colon transit times among them. An inverse correlation was observed between CVRR and the transit times for descending colon, distal colon, large intestine and whole gut. Large intestinal and whole-gut transit times were delayed in diabetics with retinopathy or with nephropathy compared to diabetics without those complications (P less than 0.01). In the diabetics, oral administration of 7.5 mg/day of cisapride for 2 weeks significantly accelerated descending colon transit (P less than 0.05) and partially accelerated distal colon, large intestinal and whole-gut transit. It is concluded that diabetics with autonomic neuropathy have delayed transits for the whole gut and that this finding is apparent to some extent in the distal colon but not in the proximal colon. Chronic oral administration of cisapride, a gastrointestinal prokinetic drug, was effective to improve these gastrointestinal motility disorders in diabetics with autonomic neuropathy.
authors.affiliation: Second Department of Internal Medicine, Osaka City University School of Medicine, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Kawagishi
authors.forename: Y
authors.initials: Y
authors.lastname: Nishizawa
authors.forename: Y
authors.initials: Y
authors.lastname: Okuno
authors.forename: K
authors.initials: K
authors.lastname: Sekiya
authors.forename: H
authors.initials: H
authors.lastname: Morii
mesh_terms: D000284:Administration, Oral; D000328:Adult; D020117:Cisapride; D003106:Colon / Q000502:physiology; D003287:Contrast Media; D003920:Diabetes Mellitus / Q000503:physiopathology*; D003928:Diabetic Nephropathies / Q000503:physiopathology; D003929:Diabetic Neuropathies / Q000503:physiopathology; D003930:Diabetic Retinopathy / Q000503:physiopathology; D005260:Female; D005769:Gastrointestinal Motility / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007421:Intestine, Small / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D003287:Contrast Media; D010880:Piperidines; D012702:Serotonin Antagonists; D020117:Cisapride